Acta Neuropharmacologica››2014,Vol. 4››Issue (1): 20-24.

Previous ArticlesNext Articles

Progress in Studies of Glutamatergic Neurotransmission in the Pathogenesis of Depression

LI Jing1, 2, SUN Jian-dong1, YUAN Yu-he1, CHEN Nai-hong1

  1. 1 State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China
    2 Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China
  • Online:2014-02-26Published:2014-06-06
  • Contact:陈乃宏,男,研究员,博士生导师;Tel.: +86-010-63165177,Fax: +86-010-63165177,E-mail: chennh@imm.ac.cn
  • About author:李婧,女,硕士研究生;研究方向:神经药理学
  • Supported by:

    国家863计划基金(No.2012AA020303),长江学者和创新团队发展计划(No.PCSIRTIRT1007),国家自然科学基金(No.81274122、No.81102831、No.81173578),国家国际科技合作项目(No.2010DFB32900),创新药物研究开发技术平台建设(No.2012ZX09301002-004、2012ZX09103101-006),教育部博士点基金重点项目(No.20121106130001),北京市自然基金重点项目(No.7131013),北京市重点实验室基金(NO.BZ0150

Abstract:The “monoamine hypothesis” of depression, which posits that depression is caused by decreased monoamine function in the brain, originated several decades ago. Although these monoamine-based agents are potent antidepressants, the cause of depression is far from being a simple deficiency of central monoamines. The glutamatergic system also plays important roles in the pathophysiology of major depressive disorder. This paper summarizes the physiological characteristics of glutamate in the brain, glutamatergic abnormalities in depression andantidepressants acting on the glutamatergic system.

Key words:major depressive disorder,glutamate,antidepressant

Baidu
map